Chungnam National University Hospital

TUESDAY, July 30, 2024 -- Overground robot-assisted gait training (RAGT) using a wearable robot improves gross motor function and gait pattern in children with cerebral palsy (CP), according to a study published online July 22 in JAMA Network Open . Ja Young Choi, M.D., Ph.D., from Chungnam National University Hospital in Daejeon, Korea, and colleagues examined the effectiveness of overground RAGT in children with CP using an untethered, torque-assisted, wearable exoskeletal robot in a multicenter, single-blind randomized trial. Ninety children were included; 78 completed the intervention, including 37 and 41 randomly assigned to the RAGT and control groups, respectively. The RAGT group underwent 18 RAGT sessions during six weeks, and the control group received the same number of standard physical therapy sessions. The researchers found that changes in the RAGT group significantly exceeded those in the control group in the Gross Motor Function Measure 88 (GMFM-88) total score, GMFM dimension E, and GMFM-66 (mean differences, 2.64, 2.70, and 1.31, respectively) and in the Pediatric Evaluation of Disability Inventory-Computer Adaptive Test responsibility domain scores (mean difference, 2.52), indicating independence in daily living at the assessment conducted postintervention. At the four-week follow-up, significantly greater improvements were seen in balance control and the Gait Deviation Index in the RAGT group versus the control group (mean differences, 1.48 and 6.48, respectively). "This new torque-assisted, wearable RAGT benefits children with CP, supporting power-as-needed control, motivating children to explore walking, and providing intensive gait training," the authors write. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Company offering discovery services for neoantigens with Neo-ARS and for full antibodies with Ab-ARSNEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Syntekabio (226330.KQ), a global artificial intelligence (AI) drug discovery pioneer, today announced its participation at the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit, where the company will highlight its novel biologics platform. The event is being held May 13-17, 2024 at the Omni Hotel at the Seaport, Boston, MA. Following the recent launch of its AI-driven drug discovery services in the US and Europe and the rollout of STB LaunchPad, Syntekabio's versatile technology platform for small molecule drug candidate generation, the company is excited to showcase its in-silico biologics discovery capabilities with Neo-ARS, its cutting-edge AI platform for personalized or universal neoantigen prediction, so-called tumor-specific cancer vaccines, as well as Ab-ARS for the prediction of novel complementarity-determining regions (CDRs) of antibody heavy chains. Jonathan Witztum, PhD, Chief Technology Officer at Syntekabio USA Inc., commented: “PEGS Boston is an excellent platform for us to present our in-silico biologics platform and our comprehensive set of AI-driven solutions for drug discovery. We look forward to engaging with leading biologics experts and discussing how our innovative technologies can positively impact therapeutics development and help to bring novel, highly effective solutions to patients.” Neo-ARS was developed in partnership with Chungnam National University Hospital, Korea and already has shown promising results in identifying and evaluating cancer neoantigens for acute myeloid leukemia (AML), demonstrating its potential in personalized immunotherapy. In a strategic move to bring these advancements to patients, Syntekabio has partnered with Metaclipse Therapeutics, a US biotechnology company developing immunotherapies for cancer and vaccines for infectious disease. The companies have signed a memorandum of understanding to initiate a joint research project, which will utilize Neo-ARS to identify highly immunogenic neoantigens, critical for the development of effective cancer vaccines and personalized immunotherapies. Ab-ARS and Neo-ARS facilitate rapid antibody prediction and optimization by leveraging a vast hydrogen-bonded peptide-peptide interaction database, as well as AI-driven 3D modeling. This is complemented by phage display experiments. Antibody heavy chains predicted by this technology, as well as personalized neoantigen-driven immunogenicity, can be used upstream to innovative therapeutic antibody designs, including bispecific T-cell engagers, multi-specific antibodies, and nanobodies. 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering SummitMay 13-17, Boston, MA, USAEngage with Syntekabio’s Innovators at Booth 40Don't miss the opportunity to meet with Syntekabio's team at Booth 40 to learn how the company’s services can find solutions to solve pipeline challenges, fast. About Syntekabio Syntekabio Co., Ltd. (KOSDAQ: 226330) is a ​drug discovery company bringing together biology and AI/ML since 2009 and facilitating the discovery of first-in-class and best-in-class compounds, rapidly. The company has its own supercomputer cloud, along with a global contract research organization network to complement and validate its computational results.​ Syntekabio offers clients a one-stop shop, with technologies and tailored services to rapidly generate and optimize drug candidates from target to IND-enabling. Syntekabio’s disease-agnostic platform generates a continual stream of hits, leads, and drug candidates that are readily available for purchase.​ The company also undertakes client-specific projects to identify highly promising development candidates for specific targets and indications. Contact Media inquiries – US & Europe: MC Services AGEurope: Dr. Cora Kaiser+49 89 210 228 0US: Laurie Doyle+1 339 832 0752 syntekabio@mc-services.eu

"AI Assistant for Radiologists" Kakao Brain introduced last month a web-based radiology report Research Use Only (RUO) service powered by its large-scale artificial intelligence (AI), "KARA-CXR." Kakao Brain plans to expand the interactive functions supporting various imaging medical examinations through the advancement of large-scale multi-modal generation AI technology. SEOUL, South Korea, Feb. 22, 2024 /PRNewswire/ -- Kakao Brain has unveiled the research use only (RUO) web-based solution powered by "KARA-CXR" (short for "Kakao Brain AI for Radiology Assistant-CXR"), a large-scale AI algorithm that instantly generates preliminary radiology reports for doctor's review when chest X-ray images are uploaded onto the web. Through this user-friendly and seamless solution, medical researchers can experience various functions such as: receiving two types of AI interpretations of chest X-ray images together (a simple report and a detailed full report); ability to upload multiple DICOM files at once and receiving multiple reports simultaneously; and being able to share the AI interpretations within the research group or medical community. It also features compliant security measures that anonymize and protect any personal information contained in DICOM files. Kakao Brain started developing 'KARA-CXR' in 2022, collaborating with 11 leading university hospitals and large medical institutions. Partners include: Ewha Womans University Medical Center (Seoul, Mok-dong), Ajou University Hospital, Soonchunhyang Medical Center (Cheonan, Gumi, Seoul), Chungnam National University Hospital, Chungbuk National University Hospital, Keimyung University Dongsan Medical Center, Inha University Hospital, Dongguk University Ilsan Hospital, among others. 'KARA-CXR' has analyzed over 16 million chest X-ray images and readings. KARA-CXR is built on Kakao Brain's healthcare-specialized large-scale generative AI model, and the research team is preparing to publish the results in influential academic journals. Kakao Brain is preparing to obtain the European Union certification and seek approval from the US FDA and Korean Ministry of Food and Drug Safety. Kakao Brain is committed to the expansion of AI-powered radiology solution to address the inefficiency in the existing interpretation and reporting process, a shortage of radiologists, and to unburden healthcare professionals from the increasing workload. As an RUO tool, KARA-CXR is currently available for research use only and is not intended to diagnose, treat, cure, or prevent any disease. Kim Il-doo, CEO of Kakao Brain, stated, "As KARA-CXR was developed using high-quality data and the latest technology involving large-scale learning and generative AI, I hope that it will eventually play a great role in enhancing the workflow for the radiologists, not to mention improving the efficiency of chest x-ray image interpretation." He also added, "We are planning to go beyond generating AI interpretations of chest X-rays by expanding the algorithms to include interactive functions that support a variety of medical imaging tests, by utilizing the advanced large-scale multi-modal generative AI technology." Kakao Brain is a Korea-based global AI technology company. Founded in 2017, Kakao Brain aims to develop AI technology that will change people's lifestyle and embraces the challenge of asking the 'Unthinkable Question' to spark innovation, allowing everyone to live better lives. Kakao Brain has developed numerous innovative AI technologies and services designed to enhance people's quality of life through continuous technological innovation. These include the large-scale language model KoGPT and the image generation model Karlo. Additionally, Kakao Brain contributes to the development of the AI technology community by releasing 'Coyo,' a dataset consisting of approximately 740 million images and text. More information about Kakao Brain can be found on their official website: . SOURCE Kakao Brain